Lymphangiogenesis and Cancer

Genes and Cancer

Volumn 2, Issue 12, 2011, Pages 1146-1158

  Christiansen, Ailsa ^a   Detmar, Michael ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

lymphatic vessels; metastasis; tumor immunity; VEGF C

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; NEUROPILIN 2; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D;

ANTIGEN PRESENTATION; CANCER GROWTH; CELL FUNCTION; CELL SUBPOPULATION; DENDRITIC CELL; DISEASE ASSOCIATION; DISTANT METASTASIS; ENDOTHELIUM CELL; FUNCTIONAL MORPHOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 84867045079     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911423028     Document Type: Review

References (153)

1. Fidler IJ,Balch CM.The biology of cancer metastasis and implications for therapy.Curr Probl Surg. 1987;24:129-209.
2. Sporn MB.The war on cancer.Lancet. 1996;347:1377-81.
3. Stacker SA,Baldwin ME,Achen MG.The role of tumor lymphangiogenesis in metastatic spread.FASEB J. 2002;16:922-34.
4. Sleeman JP,Thiele W.Tumor metastasis and the lymphatic vasculature.Int J Cancer. 2009;125:2747-56.
5. Tammela T,Alitalo K.Lymphangiogenesis: molecular mechanisms and future promise.Cell. 2010;140:460-76.
6. Cueni LN,Detmar M.New insights into the molecular control of the lymphatic vascular system and its role in disease.J Invest Dermatol. 2006;126:2167-77.
7. Wang Y,Oliver G.Current views on the function of the lymphatic vasculature in health and disease.Genes Dev. 2010;24:2115-26.
8. Swartz MA,Skobe M.Lymphatic function, lymphangiogenesis, and cancer metastasis.Microsc Res Tech. 2001;55:92-9.
9. Ran S,Volk L,Hall K,Flister MJ.Lymphangiogenesis and lymphatic metastasis in breast cancer.Pathophysiology. 2010;17:229-51.
10. Baluk P,Fuxe J,Hashizume H, et al.Functionally specialized junctions between endothelial cells of lymphatic vessels.J Exp Med. 2007;204:2349-62.
11. Gerli R,Solito R,Weber E,Agliano M.Specific adhesion molecules bind anchoring filaments and endothelial cells in human skin initial lymphatics.Lymphology. 2000;33:148-57.
12. Aukland K,Reed RK.Interstitial-lymphatic mechanisms in the control of extracellular fluid volume.Physiol Rev. 1993;73:1-78.
13. Aukland K,Nicolaysen G.Interstitial fluid volume: local regulatory mechanisms.Physiol Rev. 1981;61:556-643.
14. Schmid-Schonbein GW.Microlymphatics and lymph flow.Physiol Rev. 1990;70:987-1028.
15. Skobe M,Hawighorst T,Jackson DG, et al.Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.Nat Med. 2001;7:192-8.
16. He Y,Rajantie I,Ilmonen M, et al.Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis.Cancer Res. 2004;64:3737-40.
17. Salven P,Mustjoki S,Alitalo R,Alitalo K,Rafii S.VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells.Blood. 2003;101:168-72.
18. Cueni LN,Detmar M.The lymphatic system in health and disease.Lymphat Res Biol. 2008;6:109-22.
19. Joukov V,Pajusola K,Kaipainen A, et al.A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.EMBO J. 1996;15:290-8.
20. Orlandini M,Marconcini L,Ferruzzi R,Oliviero S.Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family.Proc Natl Acad Sci U S A. 1996;93:11675-80.
21. Yamada Y,Nezu J,Shimane M,Hirata Y.Molecular cloning of a novel vascular endothelial growth factor, VEGF-D.Genomics. 1997;42:483-8.
22. Achen MG,Jeltsch M,Kukk E, et al.Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).Proc Natl Acad Sci U S A. 1998;95:548-53.
23. Karkkainen MJ,Haiko P,Sainio K, et al.Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.Nat Immunol. 2004;5:74-80.
24. Baldwin ME,Halford MM,Roufail S, et al.Vascular endothelial growth factor D is dispensable for development of the lymphatic system.Mol Cell Biol. 2005;25:2441-9.
25. Jeltsch M,Kaipainen A,Joukov V, et al.Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.Science. 1997;276:1423-5.
26. Veikkola T,Jussila L,Makinen T, et al.Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.EMBO J. 2001;20:1223-31.
27. Dumont DJ,Jussila L,Taipale J, et al.Cardiovascular failure in mouse embryos deficient in VEGF receptor-3.Science. 1998;282:946-9.
28. Karkkainen MJ,Ferrell RE,Lawrence EC, et al.Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.Nat Genet. 2000;25:153-9.
29. Karkkainen MJ,Saaristo A,Jussila L, et al.A model for gene therapy of human hereditary lymphedema.Proc Natl Acad Sci U S A. 2001;98:12677-82.
30. Joukov V,Sorsa T,Kumar V, et al.Proteolytic processing regulates receptor specificity and activity of VEGF-C.EMBO J. 1997;16:3898-911.
31. Stacker SA,Stenvers K,Caesar C, et al.Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers.J Biol Chem. 1999;274:32127-36.
32. Cao Y,Linden P,Farnebo J, et al.Vascular endothelial growth factor C induces angiogenesis in vivo.Proc Natl Acad Sci U S A. 1998;95:14389-94.
33. Marconcini L,Marchio S,Morbidelli L, et al.c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro.Proc Natl Acad Sci U S A. 1999;96:9671-6.
34. Nagy JA,Vasile E,Feng D, et al.Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.J Exp Med. 2002;196:1497-506.
35. Hirakawa S,Hong YK,Harvey N, et al.Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells.Am J Pathol. 2003;162:575-86.
36. Hong YK,Lange-Asschenfeldt B,Velasco P, et al.VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins.FASEB J. 2004;18:1111-3.
37. Favier B,Alam A,Barron P, et al.Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration.Blood. 2006;108:1243-50.
38. Soker S,Miao HQ,Nomi M,Takashima S,Klagsbrun M.VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding.J Cell Biochem. 2002;85:357-68.
39. Pan Q,Chanthery Y,Liang WC, et al.Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.Cancer Cell. 2007;11:53-67.
40. Wang L,Zeng H,Wang P,Soker S,Mukhopadhyay D.Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration.J Biol Chem. 2003;278:48848-60.
41. Yuan L,Moyon D,Pardanaud L, et al.Abnormal lymphatic vessel development in neuropilin 2 mutant mice.Development. 2002;129:4797-806.
42. Kajiya K,Hirakawa S,Ma B,Drinnenberg I,Detmar M.Hepatocyte growth factor promotes lymphatic vessel formation and function.EMBO J. 2005;24:2885-95.
43. Morisada T,Oike Y,Yamada Y, et al.Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation.Blood. 2005;105:4649-56.
44. Tammela T,Saaristo A,Lohela M, et al.Angiopoietin-1 promotes lymphatic sprouting and hyperplasia.Blood. 2005;105:4642-8.
45. Kubo H,Cao R,Brakenhielm E,Makinen T,Cao Y,Alitalo K.Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea.Proc Natl Acad Sci U S A. 2002;99:8868-73.
46. Chang LK,Garcia-Cardena G,Farnebo F, et al.Dose- dependent response of FGF-2 for lymphangio- genesis.Proc Natl Acad Sci U S A. 2004;101:11658-63.
47. Shin JW,Min M,Larrieu-Lahargue F, et alreceptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell; 2006:576-84.
48. Cao R,Bjorndahl MA,Religa P, et al.PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis.Cancer Cell. 2004;6:333-45.
49. Bjorndahl MA,Cao R,Burton JB, et al.Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.Cancer Res. 2005;65:9261-8.
50. Fritz-Six KL,Dunworth WP,Li M,Caron KM.Adrenomedullin signaling is necessary for murine lymphatic vascular development.J Clin Invest. 2008;118:40-50.
51. Spinella F,Garrafa E,Di Castro V, et al.Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.Cancer Res. 2009;69:2669-76.
52. Clavin NW,Avraham T,Fernandez J, et al.TGF-beta1 is a negative regulator of lymphatic regeneration during wound repair.Am J Physiol Heart Circ Physiol. 2008;295:H2113-27.
53. Neuchrist C,Erovic BM,Handisurya A, et al.Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck.Head Neck. 2003;25:464-74.
54. Mohammed RA,Green A,El-Shikh S,Paish EC,Ellis IO,Martin SG.Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis.Br J Cancer. 2007;96:1092-100.
55. Schoppmann SF,Fenzl A,Nagy K, et al.VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival.Surgery. 2006;139:839-46.
56. Wartiovaara U,Salven P,Mikkola H, et al.Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.Thromb Haemost. 1998;80:171-5.
57. Mandriota SJ,Jussila L,Jeltsch M, et al.Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.EMBO J. 2001;20:672-82.
58. Stacker SA,Caesar C,Baldwin ME, et al.VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.Nat Med. 2001;7:186-91.
59. Karpanen T,Egeblad M,Karkkainen MJ, et al.Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.Cancer Res. 2001;61:1786-90.
60. He Y,Kozaki K,Karpanen T, et al.Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.J Natl Cancer Inst. 2002;94:819-25.
61. Lin J,Lalani AS,Harding TC, et al.Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.Cancer Res. 2005;65:6901-9.
62. Shimizu K,Kubo H,Yamaguchi K, et al.Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer.Cancer Sci. 2004;95:328-33.
63. Roberts N,Kloos B,Cassella M, et al.Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.Cancer Res. 2006;66:2650-7.
64. Hirakawa S,Kodama S,Kunstfeld R,Kajiya K,Brown LF,Detmar M.VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.J Exp Med. 2005;201:1089-99.
65. He Y,Rajantie I,Pajusola K, et al.Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.Cancer Res. 2005;65:4739-46.
66. Liang P,Hong JW,Ubukata H, et al.Increased density and diameter of lymphatic microvessels correlate with lymph node metastasis in early stage invasive colorectal carcinoma.Virchows Arch. 2006;448:570-5.
67. Dadras SS,Paul T,Bertoncini J, et al.Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.Am J Pathol. 2003;162:1951-60.
68. Wirzenius M,Tammela T,Uutela M, et al.Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.J Exp Med. 2007;204:1431-40.
69. Hoshida T,Isaka N,Hagendoorn J, et al.Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications.Cancer Res. 2006;66:8065-75.
70. Van der Auwera I,Van den,Eynden GG,Colpaert CG, et al.Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study.Clin Cancer Res. 2005;11:7637-42.
71. Caunt M,Mak J,Liang WC, et al.Blocking neuropilin-2 function inhibits tumor cell metastasis.Cancer Cell. 2008;13:331-42.
72. Hirakawa S,Detmar M,Kerjaschki D, et al.Nodal lymphangiogenesis and metastasis: role of tumor-induced lymphatic vessel activation in extramammary Paget's disease.Am J Pathol. 2009;175:2235-48.
73. Rinderknecht M,Detmar M.Tumor lymphangiogenesis and melanoma metastasis.J Cell Physiol. 2008;216:347-54.
74. Das S,Skobe M.Lymphatic vessel activation in cancer.Ann N Y Acad Sci. 2008;1131:235-41.
75. Travagli JP,Atallah D,Mathieu MC, et al.Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients: predictors of non-sentinel lymph node metastasis.Eur J Surg Oncol. 2003;29:403-6.
76. Ozmen V,Karanlik H,Cabioglu N, et al.Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer.Breast Cancer Res Treat. 2006;95:1-6.
77. Beriwal S,Soran A,Kocer B,Wilson JW,Ahrendt GM,Johnson R.Factors that predict the burden of axillary disease in breast cancer patients with a positive sentinel node.Am J Clin Oncol. 2008;31:34-8.
78. Schoppmann SF,Bayer G,Aumayr K, et al.Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer.Ann Surg. 2004;240:306-12.
79. Woo CS,Silberman H,Nakamura SK, et al.Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer.Am J Surg. 2002;184:337-40.
80. Kurebayashi J,Otsuki T,Kunisue H, et al.Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.Jpn J Cancer Res. 1999;90:977-81.
81. Akagi K,Ikeda Y,Miyazaki M, et al.Vascular endo thelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues.Br J Cancer. 2000;83:887-91.
82. Eggert A,Ikegaki N,Kwiatkowski J,Zhao H,Brodeur GM,Himelstein BP.High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.Clin Cancer Res. 2000;6:1900-8.
83. van der Schaft DW,Pauwels P,Hulsmans S,Zimmermann M,van de,Poll-Franse LV,Griffioen AW.Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site.Cancer Lett. 2007;254:128-36.
84. Yonemura Y,Endo Y,Fujita H, et al.Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer.Clin Cancer Res. 1999;5:1823-9.
85. Thiele W,Sleeman JP.Tumor-induced lymphangiogenesis: a target for cancer therapy?.J Biotechnol. 2006;124:224-41.
86. Nakamura Y,Yasuoka H,Tsujimoto M, et al.Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.Clin Cancer Res. 2003;9:5313-7.
87. Koyama Y,Kaneko K,Akazawa K,Kanbayashi C,Kanda T,Hatakeyama K.Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: association with lymph node metastasis.Clin Breast Cancer. 2003;4:354-60.
88. Clasper S,Royston D,Baban D, et al.A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis.Cancer Res. 2008;68:7293-303.
89. Padera TP,Kadambi A,di Tomaso E, et al.Lymphatic metastasis in the absence of functional intratumor lymphatics.Science. 2002;296:1883-6.
90. Isaka N,Padera TP,Hagendoorn J,Fukumura D,Jain RK.Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function.Cancer Res. 2004;64:4400-4.
91. Harrell MI,Iritani BM,Ruddell A.Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis.Am J Pathol. 2007;170:774-86.
92. Proulx ST,Luciani P,Derzsi S, et al.Quantitative imaging of lymphatic function with liposomal indocyanine green.Cancer Res. 2010;70:7053-62.
93. Ben-Baruch A.Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions.Breast Cancer Res. 2003;5:31-6.
94. Padera TP,Kuo AH,Hoshida T, et al.Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.Mol Cancer Ther. 2008;7:2272-9.
95. Hirakawa S,Brown LF,Kodama S,Paavonen K,Alitalo K,Detmar M.VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites.Blood. 2007;109:1010-7.
96. Qian CN,Berghuis B,Tsarfaty G, et al.Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells.Cancer Res. 2006;66:10365-76.
97. Zlotnik A,Yoshie O.Chemokines: a new classification system and their role in immunity.Immunity. 2000;12:121-7.
98. Campbell JJ,Butcher EC.Chemokines in tissue-specific and microenvironment-specific lymphocyte homing.Curr Opin Immunol. 2000;12:336-41.
99. Muller A,Homey B,Soto H, et al.Involvement of chemokine receptors in breast cancer metastasis.Nature. 2001;410:50-6.
100. Rossi D,Zlotnik A.The biology of chemokines and their receptors.Annu Rev Immunol. 2000;18:217-42.
101. Kabashima K,Shiraishi N,Sugita K, et al.CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells.Am J Pathol. 2007;171:1249-57.
102. Balkwill F.The significance of cancer cell expression of the chemokine receptor CXCR4.Semin Cancer Biol. 2004;14:171-9.
103. Staller P,Sulitkova J,Lisztwan J,Moch H,Oakeley EJ,Krek W.Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.Nature. 2003;425:307-11.
104. Schioppa T,Uranchimeg B,Saccani A, et al.Regulation of the chemokine receptor CXCR4 by hypoxia.J Exp Med. 2003;198:1391-402.
105. Cardones AR,Murakami T,Hwang ST.CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin.Cancer Res. 2003;63:6751-7.
106. Zhang JP,Lu WG,Ye F,Chen HZ,Zhou CY,Xie X.Study on CXCR4/SDF-1alpha axis in lymph node metastasis of cervical squamous cell carcinoma.Int J Gynecol Cancer. 2007;17:478-83.
107. Kaifi JT,Yekebas EF,Schurr P, et al.Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.J Natl Cancer Inst. 2005;97:1840-7.
108. Yoshitake N,Fukui H,Yamagishi H, et al.Expression of SDF-1 alpha and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer.Br J Cancer. 2008;98:1682-9.
109. Li YM,Pan Y,Wei Y, et al.Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.Cancer Cell. 2004;6:459-69.
110. Phillips RJ,Burdick MD,Lutz M,Belperio JA,Keane MP,Strieter RM.The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.Am J Respir Crit Care Med. 2003;167:1676-86.
111. Kim M,Koh YJ,Kim KE, et al.CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche.Cancer Res. 2010;70:10411-21.
112. Carlsen HS,Haraldsen G,Brandtzaeg P,Baekkevold ES.Disparate lymphoid chemokine expression in mice and men: no evidence of CCL21 synthesis by human high endothelial venules.Blood. 2005;106:444-6.
113. Link A,Vogt TK,Favre S, et al.Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells.Nat Immunol. 2007;8:1255-65.
114. Gunn MD,Tangemann K,Tam C,Cyster JG,Rosen SD,Williams LT.A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes.Proc Natl Acad Sci U S A. 1998;95:258-63.
115. Yamashita M,Iwama N,Date F, et al.Macrophages participate in lymphangiogenesis in idiopathic diffuse alveolar damage through CCL19-CCR7 signal.Hum Pathol. 2009;40:1553-63.
116. Forster R,Davalos-Misslitz AC,Rot A.CCR7 and its ligands: balancing immunity and tolerance.Nat Rev Immunol. 2008;8:362-71.
117. Gunther K,Leier J,Henning G, et al.Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7.Int J Cancer. 2005;116:726-33.
118. Takanami I.Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis.Int J Cancer. 2003;105:186-9.
119. Mashino K,Sadanaga N,Yamaguchi H, et al.Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma.Cancer Res. 2002;62:2937-41.
120. Koizumi K,Kozawa Y,Ohashi Y, et al.CCL21 promotes the migration and adhesion of highly lymph node metastatic human non-small cell lung cancer Lu-99 in vitro.Oncol Rep. 2007;17:1511-6.
121. Shields JD,Emmett MS,Dunn DB, et al.Chemokine-mediated migration of melanoma cells towards lymphatics: a mechanism contributing to metastasis.Oncogene. 2007;26:2997-3005.
122. Wiley HE,Gonzalez EB,Maki W,Wu MT,Hwang ST.Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma.J Natl Cancer Inst. 2001;93:1638-43.
123. Lanati S,Dunn DB,Roussigne M, et al.Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo.Cancer Res. 2010;70:8138-48.
124. Shields JD,Fleury ME,Yong C,Tomei AA,Randolph GJ,Swartz MA.Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling.Cancer Cell. 2007;11:526-38.
125. Miteva DO,Rutkowski JM,Dixon JB,Kilarski W,Shields JD,Swartz MA.Transmural flow modulates cell and fluid transport functions of lymphatic endothelium.Circ Res. 2010;106:920-31.
126. Tomei AA,Siegert S,Britschgi MR,Luther SA,Swartz MA.Fluid flow regulates stromal cell organization and CCL21 expression in a tissue-engineered lymph node microenvironment.J Immunol. 2009;183:4273-83.
127. Issa A,Le TX,Shoushtari AN,Shields JD,Swartz MA.Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.Cancer Res. 2009;69:349-57.
128. Mansfield AS,Holtan SG,Grotz TE, et al.Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis.Mod Pathol. 2011;24:487-94.
129. Gabrilovich DI,Chen HL,Girgis KR, et al.Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.Nat Med. 1996;2:1096-103.
130. Gabrilovich D,Ishida T,Oyama T, et al.Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.Blood. 1998;92:4150-66.
131. Gabrilovich DI,Nagaraj S.Myeloid-derived suppressor cells as regulators of the immune system.Nat Rev Immunol. 2009;9:162-74.
132. Strauss L,Volland D,Kunkel M,Reichert TE.Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.Med Sci Monit. 2005;11:.
133. Ishida T,Oyama T,Carbone DP,Gabrilovich DI.Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors.J Immunol. 1998;161:4842-51.
134. Saito H,Tsujitani S,Ikeguchi M,Maeta M,Kaibara N.Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue.Br J Cancer. 1998;78:1573-7.
135. Takahashi A,Kono K,Itakura J, et al.Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer.Oncology. 2002;62:121-7.
136. Chen Z,Varney ML,Backora MW, et al.Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival.Cancer Res. 2005;65:9004-11.
137. Ziogas AC,Gavalas NG,Tsiatas M, et al.VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2.Int J Cancer. Epub. 2011;:.
138. Nevala WK,Vachon CM,Leontovich AA,Scott CG,Thompson MA,Markovic SN.Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma.Clin Cancer Res. 2009;15:1931-9.
139. van Sandick JW,Boermeester MA,Gisbertz SS, et al.Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with adenocarcinoma of the oesophagus or oesophagogastric junction: relation to pTNM stage and clinical outcome.Cancer Immunol Immunother. 2003;52:617-24.
140. Li B,Lalani AS,Harding TC, et al.Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.Clin Cancer Res. 2006;12:6808-16.
141. Wada J,Suzuki H,Fuchino R, et al.The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.Anticancer Res. 2009;29:881-8.
142. Suzuki H,Onishi H,Wada J, et al.VEGFR2 is selectively expressed by FOXP3high CD4+ Treg.Eur J Immunol. 2010;40:197-203.
143. Manning EA,Ullman JG,Leatherman JM, et al.A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.Clin Cancer Res. 2007;13:3951-9.
144. Kalkunte SS,Mselle TF,Norris WE,Wira CR,Sentman CL,Sharma S.Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface.J Immunol. 2009;182:4085-92.
145. Ayalon O,Hughes EA,Cresswell P, et al.Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis.Proc Natl Acad Sci U S A. 1998;95:2435-40.
146. Cooper MA,Fehniger TA,Caligiuri MA.The biology of human natural killer-cell subsets.Trends Immunol. 2001;22:633-40.
147. Holtan SG,Creedon DJ,Haluska P,Markovic SN.Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.Mayo Clin Proc. 2009;84:985-1000.
148. Fletcher AL,Malhotra D,Turley SJ.Lymph node stroma broaden the peripheral tolerance paradigm.Trends Immunol. 2011;32:12-8.
149. Metzger TC,Anderson MS.Control of central and peripheral tolerance by Aire.Immunol Rev. 2011;241:89-103.
150. Cohen JN,Guidi CJ,Tewalt EF, et al.Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation.J Exp Med. 2010;207:681-8.
151. Shields JD,Kourtis IC,Tomei AA,Roberts JM,Swartz MA.Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.Science. 2010;328:749-52.
152. Randall TD,Carragher DM,Rangel-Moreno J.Development of secondary lymphoid organs.Annu Rev Immunol. 2008;26:627-50.
153. Schallenberg S,Tsai PY,Riewaldt J,Kretschmer K.Identification of an immediate Foxp3(-) precursor to Foxp3(+) regulatory T cells in peripheral lymphoid organs of nonmanipulated mice.J Exp Med. 2010;207:1393-407.